- Home
- HLN
HLN
Haleon plc (Each representing two)
as 04-02-2025 4:00pm EST
| Founded: | 2022 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $10.48 | AVG Volume (30 days): | 10.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 0.20 | EPS Growth: | 38.94 |
| 52 Week Low/High: | $7.99 - $10.80 | Next Earning Date: | 02-27-2025 |
| Revenue: | $14,062,871,660 | Revenue Growth: | -0.61% |
| Revenue Growth (this year): | 5.66% | Revenue Growth (next year): | 4.86% |
Latest Haleon plc (Each representing two) News
HLN Breaking Stock News: Dive into HLN Ticker-Specific Updates for Smart Investing
WWD
12 days ago
Former L’Oréal Executive Nathalie Gerschtein Appointed CEO U.S.A and President North America at Consumer Health Company Haleon
Zacks
12 days ago
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals
The Telegraph
13 days ago
Sensodyne-maker axes diversity targets from bonuses
Zacks
14 days ago
Pfizer Sells Remaining 7.3% Stake in Haleon for Around 3.3B
Pharmaceutical Technology
14 days ago
Pfizer sells 7.3% stake in Haleon for $3.3bn
MT Newswires
14 days ago
Top Midday Stories: EC Notifies Alphabet of DMA Noncompliance, Adopts Requirements for Apple; Boeing Expects Less Q1 Cash Outflow
MT Newswires
15 days ago
Haleon Agrees to Buy Back Over 44 Million Shares From Pfizer
GuruFocus.com
15 days ago
Pfizer Sells Final Haleon Shares for $3.2B, Ends Stake in Consumer Healthcare Giant
Compare HLN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HLN Haleon plc (Each representing two) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.